NMD3

Across TCGA pan-cancer cohorts, NMD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NMD3 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NMD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NMD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where NMD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.749	0.924	.001	43	view →
UCEC	DFS	Median	III,IV	1.000	0.424	.003	18	view →
PDAC	OS	Tertile	II,III,IV	0.555	0.913	.002	8	view →
LUAD	DFS	Median	II,III,IV	0.283	0.790	.009	7	view →
LSCC	DFS	Quartile	II,III,IV	0.356	1.000	.024	3	view →
HNSC	OS	Tertile	II,III,IV	1.000	0.953	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NMD3–CCRCC (OS)

Open the CCRCC breakdown →